Detalhe da pesquisa
1.
Patient-reported symptom monitoring: using (big) data to improve supportive care at the macro-, meso-, and micro-levels.
Support Care Cancer
; 32(3): 182, 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38386101
2.
Pro-Tumorigenic and Thrombotic Activities of Platelets in Lung Cancer.
Int J Mol Sci
; 24(15)2023 Jul 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37569299
3.
GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer.
Future Oncol
; 2022 Oct 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36268941
4.
Supportive care for new cancer therapies.
Curr Opin Oncol
; 33(4): 287-294, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33756517
5.
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type.
BMC Cancer
; 20(1): 918, 2020 Sep 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32988373
6.
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Support Care Cancer
; 28(12): 6129-6143, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32856210
7.
Cancer immunotherapy-related adverse events: causes and challenges.
Support Care Cancer
; 28(12): 6111-6117, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32857220
8.
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity.
Support Care Cancer
; 28(12): 6145-6157, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32880733
9.
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors.
Support Care Cancer
; 28(12): 6119-6128, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32856211
10.
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors.
Support Care Cancer
; 28(12): 6159-6173, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32856212
11.
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities.
Support Care Cancer
; 28(12): 6175-6181, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32856213
12.
Role of the Neutrophil in the Pathogenesis of Advanced Cancer and Impaired Responsiveness to Therapy.
Molecules
; 25(7)2020 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32244751
13.
Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy.
Int J Mol Sci
; 20(4)2019 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-30813267
14.
Neurokinin 1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant.
Future Oncol
; 14(1): 77-92, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29130344
15.
Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
Support Care Cancer
; 26(11): 3773-3780, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29808377
16.
Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence.
Future Oncol
; 12(6): 763-78, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26842387
17.
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.
Lancet Oncol
; 16(9): 1071-1078, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26272768
18.
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.
Lancet Oncol
; 16(9): 1079-1089, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26272769
19.
Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.
Oncologist
; 20(4): 450-8, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25795636
20.
MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors.
Support Care Cancer
; 28(12): 6107-6110, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32886228